Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Not Recruiting

Trial ID: NCT01514188


This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor recurrence has occurred for at least 12 months.

Official Title

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Stanford Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo

Professor of Medicine (Oncology)


Inclusion Criteria:

   - Age between 15-80 years (US only), and 18-80 (rest of world (ROW)), male or female.

   - Adjuvant or neoadjuvant chemotherapy (including doxorubicin) allowed if no tumor
   recurrence for at least 12 months since the last measurement, beginning or end of last

   - Histologically or cytologically confirmed, locally advanced, unresectable, and/or
   metastatic soft tissue sarcoma of intermediate or high grade.

   - Capable of providing informed consent and complying with trial procedures.

   - ECOG performance status 0-2.

   - Life expectancy > 12 weeks.

   - Measurable tumor lesions according to RECIST 1.1 criteria.

   - Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
   surgically sterile, or practicing adequate birth control methods) for the duration of
   the study. (Adequate contraception includes: oral contraception, implanted
   contraception, intrauterine device implanted for at least 3 months, or barrier method
   in conjunction with spermicide.)

   - Women of child bearing potential must have a negative serum or urine pregnancy test at
   the Screening Visit and be non-lactating.

   - Geographic accessibility to the site that ensures the subject will be able to keep all
   study-related appointments.

Exclusion Criteria:

   - Prior chemotherapy unless for adjuvant or neoadjuvant therapy with no tumor recurrence
   for at least 12 months.

   - Prior exposure to > 3 cycles or 225 mg/m2 of doxorubicin or Doxil®.

   - Palliative surgery and/or radiation treatment less than 4 weeks prior to

   - Exposure to any investigational agent within 30 days of Randomization.

   - Current Stage 1 or 2 soft tissue sarcomas.

   - Current evidence/diagnosis of alveolar soft part sarcoma, chondrosarcoma,
   rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST),
   dermatofibrosarcoma, Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, clear
   cell sarcomas and unresectable low grade liposarcomas.

   - Central nervous system metastasis

   - History of other malignancies except cured basal cell carcinoma, superficial bladder
   cancer or carcinoma in situ of the cervix unless documented free of cancer for > 5

   - Laboratory values: Screening serum creatinine > 1.5x upper limit of normal (ULN),
   alanine aminotransferase (ALT) > 3 × ULN or >5 × ULN if liver metastases are present,
   total bilirubin > 3 × ULN, absolute neutrophil count < 1,500/mm3, platelet
   concentration < 100,000/mm3, hematocrit level < 25% for females or < 27% for males, or
   coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT],
   International Normalized Ratio [INR]) > 1.5 × ULN, albumin < 2.0 g/dL.

   - Clinically evident congestive heart failure > class II of the New York Heart
   Association (NYHA) guidelines.

   - Current, serious, clinically significant cardiac arrhythmias, defined as the existence
   of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

   - Baseline QTc > 470 msec and/or previous history of QT prolongation while taking other
   medications. Concomitant use of medications associated with a high incidence of QT
   prolongation is not allowed.

   - History or signs of active coronary artery disease with or without angina pectoris.

   - Serious myocardial dysfunction defined as scintigraphically (e.g. MUGA, myocardial
   scintigram) or ultrasound determined absolute left ventricular ejection fraction
   (LVEF) < 45% of predicted.

   - History of HIV infection.

   - Active, clinically significant serious infection requiring treatment with antibiotics,
   anti-virals or anti-fungals.

   - Major surgery within 3 weeks prior to Randomization.

   - Substance abuse or any condition that might interfere with the subject's participation
   in the study or in the evaluation of the study results.

   - Any condition that is unstable and could jeopardize the subject's participation in the


drug: INNO-206

drug: Doxorubicin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts